Trial Profile
A Phase 2, Multicenter, Double-Blind, Randomized, Fixed Dose, Parallel Group, 3-Week Inpatient Treatment Study To Evaluate The Dose-Response Relationship, Safety, Efficacy, And Pharmacokinetics Of PF-00217830 Compared With Placebo, Using Aripiprazole As A Positive Control, In The Treatment Of Acute Exacerbation Of Schizophrenia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs PF 217830 (Primary) ; Aripiprazole
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 04 Nov 2008 Actual patient number (164) added as reported by ClinicalTrials.gov.
- 04 Nov 2008 Actual start date changed from Dec 2007 to Nov 2007 as reported by ClinicalTrials.gov.
- 03 Nov 2008 Actual patient number changed from 166 to 164 added as reported by ClinicalTrials.gov.